Healthcare

Avecho said it recommenced recruitment for the second and final patient cohort of its pivotal Phase III trial. The trial is evaluating its TPM-enhanced cannabidiol soft-gel capsule for the treatment of insomnia. The company said recruitment has restarted through its existing clinical site network, …

BlinkLab reported that individuals with a SHANK2 mutation, a group of eight participants, showed significant differences in its smartphone tests on sensorimotor gating, startle habituation and spontaneous sensorimotor behaviour. The comparison groups were 99 matched community participants, 10 unaffected siblings, or both.

On 11 November 2026, Immutep said the United States Patent andTrademarkOffice had granted patent number 12,788,796, titled Combined Preparations for the Treatment of Cancer or Infection. The company now holds five US patents within this family, following earlier grants in December 2020, March 2021, …

On 9 November 2026, Lumos announced that WellStreet Urgent Care, the sixth largest urgent care network in the United States, will roll out FebriDx to an additional 97 locations. Under WellStreet’s protocol, the test will be offered to patients presenting with acute respiratory infection …

The Indian Patent Office formally granted Patent No. 605429, titled Formulations and Methods for Treating Erectile Dysfunction. The company said the patent protects defined formulation characteristics of its intranasal technology, which supports its SPONTAN and ROXUS products. The company said the granted claims protect …

Vitasora said patients in its chronic care management program, delivered with a US Federally Qualified Health Center, were already outperforming national health center benchmarks after about six months. After about 12 months, the share of patients with poorly controlled diabetes fell from 13.1% to …

Atomo reported revenue of $1.63 million for the quarter, an increase of 140% on the prior quarter. FebriDx orders reached $680,000 in the quarter, up 314% year on year.